Crucell

Crucell was a biotechnology company specializing in vaccines and biopharmaceutical technologies.

Crucell N.V.
Privately held naamloze vennootschap; subsidiary
IndustryBiotechnology
Founded2000
HeadquartersLeiden, Netherlands
Key people
Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
ProductsVaccines and antibodies
OwnerJohnson & Johnson

History

In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2] and delisting the company from stock exchanges two months later.[3]

gollark: It's weirdly ordered, scroll up.
gollark: It has more of a dramatic flair.
gollark: Roman numerals are an entirely valid system to represent numbers, but fine.
gollark: Fine. I will add numbers to each paragraph.
gollark: You can quote from them, if you like.

References
  1. Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
  2. Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
  3. Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.